Implantable hemodynamic monitor and methods for use therewith

• US 8,328,728 B2
• Filed: 08/22/2008
• Issued: 12/11/2012
• Est. Priority Date: 08/22/2008
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Schecter, Stuart O.
• Primary Examiner(s): Gabel, Gail R
• Application Number:
  US12/196,632
• Publication Number:
  US 20100049060A1
• Time in Patent Office: 1,572 Days
• Field of Search: 600/481, 600/485, 600/486, 600/490, 600/508, 600/493, 600/500, 600/501, 600/505, 600/509, 600/513, 600/514, 600/526, 607/6, 607/17, 607/18, 607/23
• US Class Current: 600/486
• CPC Class Codes: A61B 5/02116 of pulse wave amplitude A61B5/02225 takes precedence
• CPC Class Codes: A61B 5/02125 of pulse wave propagation time
• CPC Class Codes: A61B 5/0215 by means inserted into the body catheters A61M25/00
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence

Abstract

Provided herein are implantable systems that include an implantable photoplethysmography (PPG) sensor, which can be used to obtain an arterial PPG waveform. In an embodiment, a metric of a terminal portion of an arterial PPG waveform is determined, and a metric of an initial portion of the arterial PPG waveform is determined, and a surrogate of mean arterial pressure is determined based on the metric of the terminal portion and the metric of the initial portion. In another embodiment, a surrogate of diastolic pressure is determined based on a metric of a terminal portion of an arterial PPG waveform. In a further embodiment, a surrogate of cardiac afterload is determined based on a metric of a terminal portion of an arterial PPG waveform.

Claims

1. For use in an implantable system including an implantable photoplethysmography (PPG) sensor, a method for determining a surrogate of cardiac afterload (CA) in a subject, comprising:

(a) obtaining an arterial PPG waveform measurement using the implantable PPG sensor implanted in the subject;

(b) determining a metric of a terminal portion of the arterial photoplethysmography (PPG) waveform, wherein the terminal portion is from a maximum of the arterial PPG waveform to the following minimum of the PPG waveform; and

(c) determining the surrogate of CA in the subject as a function of the metric of the terminal portion of the arterial PPG waveform in step b) based on the measured arterial PPG waveform by the implanted PPG sensor.

2. The method of claim 1, wherein the arterial PPG waveform comprises an averaged arterial PPG waveform that is produced by averaging a plurality of cardiac cycles of a PPG signal obtained from the implanted PPG sensor.

3. The method of claim 1, further comprising:

repeating steps (a) and (b) and (c) from time to time; and

monitoring changes in CA by monitoring changes in the surrogate of CA as steps (a) and (b) and (c) are repeated from time to time.

4. The method of claim 1, wherein, the metric of the terminal portion comprises at least one of the following:

an integral from a maximum to the following minimum of the arterial PPG waveform;

an integral from a dicrotic notch to the following minimum of the PPG waveform;

a terminal deceleration slope (TDS), which is a downward slope from a maximum to the following minimum of the arterial PPG waveform;

a beginning terminal deceleration slope (BTDS), which is a downward slope from a maximum to the following dicrotic notch of the arterial PPG waveform;

a total relaxation time (TRT), which is a time from a maximum to the following minimum of the atrial PPG signal; and

a terminal deceleration time (TeDT), which is a time from a dicrotic notch to the following minimum of the atrial PPG signal.